150 results on '"Ionova, Tatyana"'
Search Results
2. Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review
3. Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials
4. P1688: LIVING WITH ACUTE LEUKEMIA: A GLOBAL SURVEY OF PATIENTS AND CARERS EXPERIENCE
5. PB2705: PROFESSIONAL BURNOUT AMONG HEMATOLOGISTS AFTER THE OUTBREAK OF THE COVID-19 PANDEMIC AND ASSOCIATED FACTORS
6. P1693: PATIENT-REPORTED OUTCOMES IN LYMPHOMA TRIALS: A SYSTEMATIC REVIEW
7. P1692: UNMET NEEDS IN PATIENTS WITH “LOW RISK” POLYCYTHEMIA VERA (PV): SYMPTOM BURDEN AND QUALITY OF LIFE
8. PB2673: EXPERIENCES AND VIEWS OF LEUKEMIA CARERS: A GLOBAL SURVEY
9. Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials
10. Understanding Quality of Life in Patients With Acute Leukemia, a Global Survey
11. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives
12. PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY.
13. Patient-reported outcomes in clinical trials for multiple myeloma: Where we are.
14. Patient-reported outcomes in clinical trials for multiple myeloma: Where we are.
15. Quality of Life (QoL) and Clinical Outcomes in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Ixazomib-Lenalidomide-Dexamethasone (IRd) in a Real-World Setting
16. Investigating the Quality of Life of Patients with Acute Leukemia, with a Focus on Age and Patient-Reported Experience
17. Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
18. Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study
19. Attitudes to the disease and therapy in patients with chronic Ph-negative myeloproliferative neoplasms: results of the physician and patient surveys in Russia as a part of International Landmark Study
20. Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity
21. Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study
22. The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial
23. Identifying Differences in the Quality of Life of Patients with Acute Leukemia: A Global Survey
24. Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting
25. Withdrawal Syndrome After Tyrosine Kinase Inhibitors Discontinuation in Patients with Chronic Myeloid Leukemia in Russian Prospective Study (RU-SKI)
26. Multicenter observational prospective study of nivolumab (Nivo) as 2+ line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes.
27. Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study
28. EFFICACY OF NIVOLUMAB (NWO) DURING 2+ LINE TREATMENT AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED REFRACTORY NON-SMALL CELL LUNG CANCER: INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY
29. Proceedings of Patient Reported Outcome Measure’s (PROMs) Conference Oxford 2017: Advances in Patient Reported Outcomes Research
30. Proceedings of Patient Reported Outcome Measure’s (PROMs) Conference Oxford 2017: Advances in Patient Reported Outcomes Research : Oxford, UK. 8th June 2017
31. Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies
32. Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies
33. Impact of AML on Patients' Lives: The Value of HM-PRO Measurements
34. Efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.
35. The effect of medical social rehabilitation on quality of life in children with brain tumors: Interim results of observational prospective study.
36. Stem Cell Transplantation in Multiple Sclerosis: Sharing the Experience
37. Observational study of the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis.
38. Quality of Life (QoL) and Clinical Outcomes of Dasatinib Treatment in TKI-Naive and Early Switched from Imatinib Patients with Chronic Myeloid Leukemia in Chronic Phase (CP CML) in a Real World Setting
39. Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation
40. Challenges of Assessing Symptom Burden in Patients with Haematological Malignancies
41. Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities
42. Patient-Reported Outcomes in Myelofibrosis Patients Help to Identify Patients' Needs
43. HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice
44. Long-Term Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia from Physician’s and Patient’s Perspective
45. Efficacy Of Dasatinib Therapy In Patients With Imatinib-Resistant Or -Intolerant Chronic Myeloid Leukemia From Physician’s and Patient’s Perspective: “Real World” Data
46. Understanding the Importance of Using Patient-Reported Outcome Measures in Patients With Immune Thrombocytopenia
47. Clinical and Patient-Reported Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia
48. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis
49. Reduced Intensity Conditioning Regimen of Autologous Hematopoietic Stem Cell Transplantation±Mitoxantrone Consolidation In Multiple Sclerosis
50. New Instrument for Comprehensive Symptom Profile Assessment In Patients with Malignant Lymphomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.